In this article, we will discuss Olaparib (Hepatic Impairment). So, let’s get started. Hepatic Impairment No adjustment to the starting dose is required in patients with mild hepatic impairment. A 15% increase in mean exposure (AUC) was observed in patients with mild hepatic impairment (based on Child-Pugh classification A) compared to patients with normal hepatic […]
Category: Olaparib
In this article, we will discuss Olaparib (Geriatric Use). So, let’s get started. Geriatric Use In clinical studies of Olaparib enrolling 687 patients with advanced solid tumors who received Olaparib tablets 300 mg twice daily as monotherapy, 146 (21%) patients were aged ≥65 years, and this included 29 (4%) patients who were aged ≥75 years. […]
In this article, we will discuss Olaparib (Pediatric Use). So, let’s get started. Pediatric Use The safety and efficacy of Olaparib have not been established in pediatric patients.
In this article we will discuss Olaparib (Drug Interaction-7). So, let’s get started. Avoid concomitant use of strong CYP3A inducers such as phenytoin, rifampicin, carbamazepine, and St. John’s Wort or moderate CYP3A4 inducers such as bosentan, efavirenz, etravirine, modafinil, and nafcillin. If a moderate CYP3A inducer cannot be avoided, there is a potential for decreased […]
In this article, we will discuss Olaparib (Drug Interaction-6). So, let’s get started. Drugs That May Decrease Olaparib Plasma Concentrations In patients (n=22), co-administration of rifampicin, a strong CYP3A inducer, decreased AUC of olaparib by 87%. A moderate CYP3A inducer, efavirenz, is predicted to decrease the AUC of olaparib by approximately 60%.
In this article, we will discuss Olaparib (Drug Interaction-5). So, let’s get started. Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during Olaparib treatment since they are CYP3A inhibitors.